Who is sponsoring NCT02340156?

NCT02340156 is sponsored by SynerGene Therapeutics, Inc..

What condition does NCT02340156 study?

NCT02340156 studies RECURRENT GLIOBLASTOMA.

What drugs are being tested in NCT02340156?

Interventions: SGT-53, Temozolomide.

What is the status of NCT02340156?

NCT02340156 is currently TERMINATED.

Last reviewed 2021-02-11 · How we verify

Phase II Study of Combined Temozolomide and Targeted P53 Gene Therapy (SGT-53) for Treatment of Patients With Recurrent Glioblastoma

NCT02340156 Phase 2 TERMINATED Results posted

This Phase II clinical trial is an open label, single arm, multicenter study of the combination of intravenously administered SGT-53 and oral temozolomide in patients with confirmed glioblastoma who have proven tumor recurrence or progression. The objective of this trial is to assess 6 month progression free survival (PFS), overall survival (OS), anti-tumor activity, safety and possibly to evaluate, nanoparticle delivery to tumor site, and the induction of apoptosis in the tumor..

Details

Lead sponsor	SynerGene Therapeutics, Inc.
Phase	Phase 2
Status	TERMINATED
Enrolment	1
Start date	2014-12
Completion	2018-11

Conditions

RECURRENT GLIOBLASTOMA

Interventions

SGT-53
Temozolomide

Primary outcomes

Tumor Response — 6 months
The 6 month progression-free survival (PFS) was evaluated using RANO Response Criteria.

Countries

United States, Taiwan